Top

Published in:

01-07-2016 | Review Article

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

Authors: Kelvin Yi Chong Teo, Wei Yan Ng, Shu Yen Lee, Chui Ming Gemmy Cheung

Published in: Drugs | Issue 11/2016

Abstract

Myopic choroidal neovascularization (mCNV) is the second most common form of CNV after age-related macular degeneration (AMD). It is a sight-threatening complication of pathologic myopia (PM) and often affects patients in their working years causing significant impact on quality of life. Previous therapies such as photodynamic therapy with verteporfin have shown limited success. Due to the similarities in pathogenesis of mCNV and AMD CNV, anti-vascular endothelial growth factor therapy (anti-VEGF), which has so far been the mainstay of treatment for AMD CNV, has been shown to be effective in the treatment of mCNV and has become the first-line treatment of choice. This article aims to examine briefly the epidemiology and pathophysiology of mCNV, as well as review the evidence for efficacy, safety, and clinical use of anti-VEGF treatment for mCNV.

Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012;379(9827):1739–48. doi:10.1016/S0140-6736(12)60272-4.CrossRefPubMed

Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157(1):9–25 e12. doi:10.1016/j.ajo.2013.08.010.

Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial–VIP report no. 3. Ophthalmology. 2003;110(4):667–73.CrossRefPubMed

Lai TY. Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence? Retina. 2012;32(8):1443–5. doi:10.1097/IAE.0b013e31826956e4.CrossRefPubMed

Baldwin WR. A review of statistical studies of relations between myopia and ethnic, behavioral, and physiological characteristics. Am J Optom Physiol Opt. 1981;58(7):516–27.CrossRefPubMed

Wolfram C, Hohn R, Kottler U, Wild P, Blettner M, Buhren J, et al. Prevalence of refractive errors in the European adult population: the Gutenberg Health Study (GHS). Br J Ophthalmol. 2014;98(7):857–61. doi:10.1136/bjophthalmol-2013-304228.CrossRefPubMed

Pan CW, Cheng CY, Saw SM, Wang JJ, Wong TY. Myopia and age-related cataract: a systematic review and meta-analysis. Am J Ophthalmol. 2013;156(5):1021–33 e1. doi:10.1016/j.ajo.2013.06.005.

Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ. 2008;86(1):63–70.CrossRefPubMedPubMedCentral

Liu HH, Xu L, Wang YX, Wang S, You QS, Jonas JB. Prevalence and progression of myopic retinopathy in Chinese adults: the Beijing Eye Study. Ophthalmology. 2010;117(9):1763–8. doi:10.1016/j.ophtha.2010.01.020.CrossRefPubMed

10.

Ohno-Matsui K, Kawasaki R, Jonas JB, Cheung CM, Saw SM, Verhoeven VJ, et al. International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol. 2015;159(5):877–83. doi:10.1016/j.ajo.2015.01.022.CrossRefPubMed

11.

Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984;91(12):1573–81.CrossRefPubMed

12.

Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2004;111(1):62–9. doi:10.1016/j.ophtha.2003.05.011.CrossRefPubMed

13.

Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y, et al. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. Ophthalmology. 2006;113(8):1354–62. doi:10.1016/j.ophtha.2006.04.022.CrossRefPubMed

14.

Curtin BJ, Karlin DB. Axial length measurements and fundus changes of the myopic eye. Am J Ophthalmol. 1971;71(1 Pt 1):42–53.CrossRefPubMed

15.

Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Kojima A, Hayashi W, et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology. 2010;117(8):1595–611, 611 e1–4. doi:10.1016/j.ophtha.2009.11.003.

16.

Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31(5):495–525. doi:10.1016/j.preteyeres.2012.04.001.CrossRefPubMed

17.

Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2003;87(5):570–3.CrossRefPubMedPubMedCentral

18.

Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol. 1981;91(2):177–83.CrossRefPubMed

19.

Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141(3):456–62. doi:10.1016/j.ajo.2005.10.012.CrossRefPubMed

20.

Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151(1):281–91.PubMedPubMedCentral

21.

Moriyama M, Ohno-Matsui K, Futagami S, Yoshida T, Hayashi K, Shimada N, et al. Morphology and long-term changes of choroidal vascular structure in highly myopic eyes with and without posterior staphyloma. Ophthalmology. 2007;114(9):1755–62. doi:10.1016/j.ophtha.2006.11.034.CrossRefPubMed

22.

Xu L, Li Y, Wang S, Wang Y, Wang Y, Jonas JB. Characteristics of highly myopic eyes: the Beijing Eye Study. Ophthalmology. 2007;114(1):121–6. doi:10.1016/j.ophtha.2006.05.071.CrossRefPubMed

23.

You QS, Peng XY, Xu L, Chen CX, Wang YX, Jonas JB. Myopic maculopathy imaged by optical coherence tomography: the beijing eye study. Ophthalmology. 2014;121(1):220–4. doi:10.1016/j.ophtha.2013.06.013.CrossRefPubMed

24.

Curtin BJ. Physiologic vs pathologic myopia: genetics vs environment. Ophthalmology. 1979;86(5):681–91.CrossRefPubMed

25.

Seko Y, Seko Y, Fujikura H, Pang J, Tokoro T, Shimokawa H. Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci. 1999;40(13):3287–91.PubMed

26.

Wakabayashi T, Ikuno Y. Choroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Ophthalmol. 2010;94(5):611–5. doi:10.1136/bjo.2009.163535.CrossRefPubMed

27.

Young TL. Dissecting the genetics of human high myopia: a molecular biologic approach. Trans Am Ophthalmol Soc. 2004;102:423–45.PubMedPubMedCentral

28.

Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology. 1983;90(8):923–6.CrossRefPubMed

29.

Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997;7(4):307–16.PubMed

30.

Teo K, Gemmy Cheung C. Choroidal neovascularization secondary to pathological myopia. World J Ophthalmol. 2014;4(3):35–46.

31.

Ikuno Y, Sayanagi K, Soga K, Sawa M, Gomi F, Tsujikawa M, et al. Lacquer crack formation and choroidal neovascularization in pathologic myopia. Retina. 2008;28(8):1124–31. doi:10.1097/IAE.0b013e318174417a.CrossRefPubMed

32.

Cheung CM, Loh BK, Li X, Mathur R, Wong E, Lee SY, et al. Choroidal thickness and risk characteristics of eyes with myopic choroidal neovascularization. Acta Ophthalmol. 2013;91(7):e580–1. doi:10.1111/aos.12117.CrossRefPubMed

33.

Kim YM, Yoon JU, Koh HJ. The analysis of lacquer crack in the assessment of myopic choroidal neovascularization. Eye. 2011;25(7):937–46. doi:10.1038/eye.2011.94.CrossRefPubMedPubMedCentral

34.

Bruyere E, Caillaux V, Cohen SY, Martiano D, Ores R, Puche N, et al. Spectral-domain optical coherence tomography of subretinal hyperreflective exudation in myopic choroidal neovascularization. Am J Ophthalmol. 2015;160(4):749–58. doi:10.1016/j.ajo.2015.07.004.CrossRefPubMed

35.

Milani P, Pece A, Pierro L, Bergamini F. Imaging of naive myopic choroidal neovascularization by spectral-domain optical coherence tomography. Ophthalmol J Int d’ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde. 2014;232(1):28–36. doi:10.1159/000357980.CrossRef

36.

Baba T, Ohno-Matsui K, Yoshida T, Yasuzumi K, Futagami S, Tokoro T, et al. Optical coherence tomography of choroidal neovascularization in high myopia. Acta Ophthalmol Scand. 2002;80(1):82–7.CrossRefPubMed

37.

Hee MR, Baumal CR, Puliafito CA, Duker JS, Reichel E, Wilkins JR, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology. 1996;103(8):1260–70.CrossRefPubMed

38.

Ohno-Matsui K, Ito M, Tokoro T. Subretinal bleeding without choroidal neovascularization in pathologic myopia. A sign of new lacquer crack formation. Retina. 1996;16(3):196–202.CrossRefPubMed

39.

Leung TG, Moradi A, Liu D, Nguyen QD, Dunn JP, Burkholder B, et al. Clinical features and incidence rate of ocular complications in punctate inner choroidopathy. Retina. 2014;34(8):1666–74. doi:10.1097/IAE.0000000000000125.CrossRefPubMed

40.

Watzke RC, Packer AJ, Folk JC, Benson WE, Burgess D, Ober RR. Punctate inner choroidopathy. Am J Ophthalmol. 1984;98(5):572–84.CrossRefPubMed

41.

Vance SK, Khan S, Klancnik JM, Freund KB. Characteristic spectral-domain optical coherence tomography findings of multifocal choroiditis. Retina. 2011;31(4):717–23. doi:10.1097/IAE.0b013e318203c1ef.CrossRefPubMed

42.

Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103(8):1241–4.CrossRefPubMed

43.

Mauget-Faysse M, Cornut PL, Quaranta El-Maftouhi M, Leys A. Polypoidal choroidal vasculopathy in tilted disk syndrome and high myopia with staphyloma. Am J Ophthalmol. 2006;142(6):970–5. doi:10.1016/j.ajo.2006.06.063.CrossRefPubMed

44.

Kang HM, Koh HJ. Lack of polypoidal lesions in patients with myopic choroidal neovascularization as evaluated by indocyanine green angiography. Am J Ophthalmol. 2014;157(2):378–83 e1. doi:10.1016/j.ajo.2013.09.018.

45.

Caillaux V, Gaucher D, Gualino V, Massin P, Tadayoni R, Gaudric A. Morphologic characterization of dome-shaped macula in myopic eyes with serous macular detachment. Am J Ophthalmol. 2013;156(5):958–67 e1. doi:10.1016/j.ajo.2013.06.032.

46.

Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110(7):1297–305. doi:10.1016/s0161-6420(03)00461-5.CrossRefPubMed

47.

Kojima A, Ohno-Matsui K, Teramukai S, Ishihara Y, Shimada N, Yoshida T, et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2006;244(11):1474–9. doi:10.1007/s00417-006-0324-4.

48.

Ohno-Matsui K, Yoshida T. Myopic choroidal neovascularization: natural course and treatment. Curr Opin Ophthalmol. 2004;15(3):197–202.CrossRefPubMed

49.

Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol. 2005;89(11):1522–8. doi:10.1136/bjo.2005.074716.CrossRefPubMedPubMedCentral

50.

Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101(12):1953–61.CrossRefPubMed

51.

Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Luke M, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006;142(1):95–104. doi:10.1016/j.ajo.2006.01.085.CrossRefPubMed

52.

Adelberg DA, Del Priore LV, Kaplan HJ. Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders. Retina. 1995;15(3):198–205.CrossRefPubMed

53.

Thomas MA, Dickinson JD, Melberg NS, Ibanez HE, Dhaliwal RS. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology. 1994;101(8):1384–96.CrossRefPubMed

54.

Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol. 2000;118(3):344–50.CrossRefPubMed

55.

Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol. 2002;133(4):530–6.CrossRefPubMed

56.

Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80(3):241–5.CrossRefPubMedPubMedCentral

57.

Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81(2):154–62.CrossRefPubMedPubMedCentral

58.

Bennett MD, Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2007;245(6):903–5. doi:10.1007/s00417-006-0472-6.

59.

Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina. 2008;28(9):1308–13. doi:10.1097/IAE.0b013e31818358b2.CrossRefPubMed

60.

Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR Study. Ophthalmology. 2015;122(6):1220–7. doi:10.1016/j.ophtha.2015.01.025.CrossRefPubMed

61.

Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682–92 e2. doi:10.1016/j.ophtha.2013.10.023.

62.

Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009;147(1):94–100 e1. doi:10.1016/j.ajo.2008.07.017.

63.

Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol. 2009;93(2):150–4. doi:10.1136/bjo.2008.145797.CrossRefPubMed

64.

Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol. 2009;93(4):448–51. doi:10.1136/bjo.2008.145391.CrossRefPubMed

65.

Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina. 2009;29(6):750–6. doi:10.1097/IAE.0b013e31819ed6bd.CrossRefPubMed

66.

Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab–a randomized controlled trial. Am J Ophthalmol. 2010;149(3):458–64 e1. doi:10.1016/j.ajo.2009.10.010.

67.

Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina. 2012;32(8):1539–46. doi:10.1097/IAE.0b013e31826956b7.CrossRefPubMed

68.

Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120(9):1944–5 e1. doi:10.1016/j.ophtha.2013.06.010.

69.

Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina. 2013;33(7):1375–92. doi:10.1097/IAE.0b013e31827d260a.CrossRefPubMed

70.

Gharbiya M, Allievi F, Conflitti S, Esposito M, Scavella V, Moramarco A, et al. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. La Clinica terapeutica. 2010;161(3):e87–93.PubMed

71.

Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Retina. 2011;31(9):1841–7. doi:10.1097/IAE.0b013e31821800a4.CrossRefPubMed

72.

Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez-Lopez F, Rodriguez M, et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye. 2009;23(2):334–8. doi:10.1038/sj.eye.6703052.CrossRefPubMed

73.

Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye. 2012;26(7):1004–11. doi:10.1038/eye.2012.97.CrossRefPubMedPubMedCentral

74.

Franqueira N, Cachulo ML, Pires I, Fonseca P, Marques I, Figueira J, et al. Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica J Int d’ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde. 2012;227(1):39–44. doi:10.1159/000333213.CrossRef

75.

Oishi A, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Nakata I, et al. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2013;251(1):1–7. doi:10.1007/s00417-012-2022-8.

76.

Yang HS, Kim JG, Kim JT, Joe SG. Prognostic factors of eyes with naive subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am J Ophthalmol. 2013;156(6):1201–10 e2. doi:10.1016/j.ajo.2013.08.002.

77.

Ruiz-Moreno JM, Montero JA, Amat-Peral P. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2011;249(4):595–9. doi:10.1007/s00417-010-1599-z.

78.

Wakabayashi T, Ikuno Y, Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina. 2011;31(5):880–6. doi:10.1097/IAE.0b013e3181f2a293.CrossRefPubMed

79.

Niwa Y, Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, et al. Comparison between one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Res. 2012;47(3):135–40. doi:10.1159/000330499.CrossRefPubMed

80.

Kung YH, Wu TT, Huang YH. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol. 2014;92(8):e615–20. doi:10.1111/aos.12457.CrossRefPubMed

81.

Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology. 2012;119(10):2082–6. doi:10.1016/j.ophtha.2012.07.041.CrossRefPubMed

82.

Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina. 2010;30(3):418–24. doi:10.1097/IAE.0b013e3181bd2fe4.CrossRefPubMed

83.

Chen L, Miller JW, Vavvas D, Kim IK. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration. Retina. 2011;31(10):2078–83. doi:10.1097/IAE.0b013e3182109074.CrossRefPubMed

84.

Peiretti E, Vinci M, Fossarello M. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol J Canadien d’ophtalmologie. 2012;47(1):28–33. doi:10.1016/j.jcjo.2011.12.009.CrossRef

85.

Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol. 2013;97(11):1447–50. doi:10.1136/bjophthalmol-2012-302973.CrossRefPubMed

86.

Ruiz-Moreno JM, Montero JA, Araiz J, Arias L, Garcia-Layana A, Carneiro A, et al. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: six years outcome. Retina. 2015. doi:10.1097/iae.0000000000000632.

87.

Sarao V, Veritti D, Macor S, Lanzetta P. Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2016;254(3):445–54. doi:10.1007/s00417-015-3076-1.

88.

Calvo-Gonzalez C, Reche-Frutos J, Donate J, Fernandez-Perez C, Garcia-Feijoo J. Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am J Ophthalmology. 2011;151(3):529–34. doi:10.1016/j.ajo.2010.09.021.CrossRef

89.

Ahn SJ, Park KH, Woo SJ. Subfoveal choroidal thickness changes following anti-vascular endothelial growth factor therapy in myopic choroidal neovascularization. Invest Ophthalmol Vis Sci. 2015;56(10):5794–800. doi:10.1167/iovs.14-16006.CrossRefPubMed

90.

Uemoto R, Nakasato-Sonn H, Kawagoe T, Akira M, Okada E, Mizuki N. Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2012;250(7):989–97. doi:10.1007/s00417-011-1921-4.

91.

Ohno-Matsui K, Jonas JB, Spaide RF. Macular Bruch’s membrane holes in highly myopic patchy chorioretinal atrophy. Am J Ophthalmol. 2016. doi:10.1016/j.ajo.2016.03.019.

92.

Saviano S, Piermarocchi R, Leon PE, Mangogna A, Zanei A, Cavarzeran Sc F, et al. Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study. Int J Ophthalmol. 2014;7(2):335–9. doi:10.3980/j.issn.2222-3959.2014.02.26.PubMedPubMedCentral

93.

Voykov B, Gelisken F, Inhoffen W, Voelker M, Bartz-Schmidt KU, Ziemssen F. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years? Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2010;248(4):543–50. doi:10.1007/s00417-009-1285-1.

94.

Nakanishi H, Tsujikawa A, Yodoi Y, Ojima Y, Otani A, Tamura H, et al. Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye. 2011;25(3):375–81. doi:10.1038/eye.2010.226.

95.

Ruiz-Moreno JM, Lopez-Galvez MI, Donate J, Gomez-Ulla F, Garcia-Arumi J, Garcia-Layana A, et al. Myopic choroidal neovascularization. Ophthalmology. 2011;118(12):2521–3. doi:10.1016/j.ophtha.2011.07.029.CrossRefPubMed

96.

Gharbiya M, Cruciani F, Parisi F, Cuozzo G, Altimari S, Abdolrahimzadeh S. Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2012;96(8):1068–72. doi:10.1136/bjophthalmol-2012-301639.CrossRefPubMed

97.

Milani P, Massacesi A, Ciaccia S, Setaccioli M, Moschini S, Bergamini F. Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naive myopic choroidal neovascularization. Clin Ophthalmol. 2012;6:1885–94. doi:10.2147/OPTH.S34649.CrossRefPubMedPubMedCentral

98.

Farinha CL, Baltar AS, Nunes SG, Franqueira NF, Figueira JP, Pires IA, et al. Choroidal thickness after treatment for myopic choroidal neovascularization. Eur J Ophthalmol. 2013;23(6):887–98. doi:10.5301/ejo.5000323.PubMed

99.

Wang J, Kang Z. Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2012;250(12):1717–23. doi:10.1007/s00417-012-2159-5.

100.

Ahn SJ, Woo SJ, Kim KE, Park KH. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization. Invest Ophthalmol Vis Sci. 2013;54(3):2115–22. doi:10.1167/iovs.12-11542.CrossRefPubMed

101.

Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol. 2011;89(1):70–5. doi:10.1111/j.1755-3768.2010.02064.x.CrossRefPubMed

102.

Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. 2010;88(4):e136. doi:10.1111/j.1755-3768.2009.01572.x.CrossRefPubMed

103.

Rosen E, Rubowitz A, Ferencz JR. Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye. 2009;23(6):1479. doi:10.1038/eye.2008.218.CrossRefPubMed

104.

Tokoro T. On the definition of pathologic myopia in group studies. Acta Ophthalmol Suppl. 1988;185:107–8.PubMed

105.

Amoaku WM, Gale RP, Lotery AJ, Menon G, Sivaprasad S, Petrillo J, et al. Treatment satisfaction and well-being in patients with myopic choroidal neovascularization treated with ranibizumab in the REPAIR Study. PLoS One. 2015;10(6):e0128403. doi:10.1371/journal.pone.0128403.CrossRefPubMedPubMedCentral

106.

Parodi MB, Iacono P, Papayannis A, Kontadakis S, Cascavilla ML, Zucchiatti I, et al. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia. Retina. 2013;33(3):593–7. doi:10.1097/IAE.0b013e31826b6731.CrossRefPubMed

107.

Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol. 2010;149(1):140–6. doi:10.1016/j.ajo.2009.08.008.CrossRefPubMed

Title: Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy
Authors: Kelvin Yi Chong Teo
Wei Yan Ng
Shu Yen Lee
Chui Ming Gemmy Cheung
Publication date: 01-07-2016
Publisher: Springer International Publishing
Published in: Drugs / Issue 11/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-016-0605-0

At a glance: The STEP trials

Springer Medicine

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2016

Migalastat: First Global Approval

Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management

Secukinumab: A Review in Psoriatic Arthritis

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation

Olmutinib: First Global Approval

Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm